newsfilter
← Latest News
GlobeNewswire·

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

  • All eight treated recurrent glioblastoma patients in the REGAIN trial remain alive as of November 11, 2026, with median overall survival not yet reached & median follow-up of 6.9 months for six patients who reached response assessment.
  • Six patients who reached response assessment achieved a RANO objective response: five showed complete responses (83.3%) & one showed a partial response (16.7%) with a 58% tumor measurement decrease.
  • Primary endpoints of feasibility & safety were met: Alpha DaRT sources were successfully deployed in 100% of patients, with no unanticipated serious adverse events observed.
  • Follow-up scans revealed asymptomatic radiation necrosis in four of six evaluable patients, a known effect of focal radiation, while investigators are monitoring two patients to distinguish between necrosis & potential tumor progression.
  • No definitive local tumor recurrence was observed in any treated patient as of the cutoff date, though one patient experienced progression outside the treated area nine months post-treatment.
  • The trial is enrolling up to 20 patients at The Ohio State University Comprehensive Cancer Center, with enrollment & follow-up ongoing.
  • A conference call with principal investigator Dr. Joshua Palmer & company management is scheduled for Monday, November 16, 2026, at 8:30 am ET to discuss these interim results.
Company
Alpha Tau Medical Ltd.
Keywords
Nasdaq:DRTS , Alpha Tau Medical Ltd., Alpha DaRT, alpha radiation, Glioblastoma, GBM, alpha tau, clinical trials, Recurrent glioblastoma, Recurrent GBM, rGBM